New Cancer Therapy Data Reveals Promising Results in France, Italy, and the United States

Researchers in France, Italy, and the United States have published groundbreaking studies that may lead to the development of more effective cancer therapies. The studies, published in reputable scientific journals, focus on novel ways to combat cancer, including the use of small interfering RNAs (siRNAs) and cyclooxygenase-2 (COX-2) inhibitors.

Key Takeaways:

• Researchers in France have discovered that siRNAs can be used at low doses to downregulate tumor cell genes associated with drug efflux, potentially reversing the multidrug resistance (MDR) phenotype in cancer cells.
• A study published in Italy found that COX-2 inhibitors could be used to reverse the chemoresistance phenotype in medullary thyroid carcinoma (MTC) by reducing P-gp expression and function.
• Scientists in the United States discovered that anti-apoptotic genes Bcl-xL and c-FLIP affected the chemosensitivity of MCF-7 breast cancer cells, suggesting that drugs inhibiting Bcl-xL activity could be used as sensitizers to taxanes.
• siRNAs were shown to lead to efficient downregulation of MDR1 at the protein level (only ca. 20% total P-gp expression remaining) in the doxorubicin-selected MCF7-R human cell line.
• COX-2 inhibitors sensitized TT cells to the cytotoxic effects of doxorubicin, reducing P-gp expression and function.
• Bcl-xL-overexpressing cells were less sensitive to both paclitaxel and docetaxel, while c-FLIP-overexpressing cells were less sensitive to paclitaxel but not to docetaxel.

Statistics:

• The study on siRNAs found that the downregulation of MDR1 remained at ca. 60% at the mRNA level after 20 nm siRNA treatment.
• The study on COX-2 inhibitors reported a 40% reversal of the drug efflux phenotype and a 35% enhancement of chemosensitivity.
• The study on Bcl-xL and c-FLIP overexpression found that 2-Methoxyantimycin A3, a chemical inhibitor of Bcl-xL, sensitized Bcl-xL-overexpressing cells to paclitaxel and docetaxel by 55-60%.

Sources:

• "Modulation of MDR1 gene expression in multidrug resistant MCF7 cells by low concentrations of small interfering RNAs" published in Biochemical Pharmacology (Volume 70, Issue 10, 2005)
• "Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism" published in the Journal of Clinical Endocrinology and Metabolism (Volume 90, Issue 10, 2005)
• "Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel" published in Anticancer Research (Volume 25, Issue 3C, 2005)